News

Under the deal, Incyte will make a $140m upfront payment to Ariad plus pay royalties of up to 50% on European sales of Iclusig. Incyte will also take

Janssen Biotech and AbbVie company Pharmacyclics are jointly developing and commercializing Imbruvica, which blocks a specific protein called Bruton’s tyrosine kinase. The Imbruvica labeling now includes OS results

Hotung Group, and CDIB Capital Management, led the round with continued participation from existing investors, Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital

As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used for the treatment

The study (NCT02415127) has reached its target enrollment of 90 patients at four sites in the United States, and top-line results are expected by the end of 2016.

Cardiome will provide Allergan with a staggered upfront payment totalling US$13 million and will provide Allergan additional milestone payments and royalties based upon commercial achievements and sales of

The company’s lead compound ALLN-177, an oral formulation of oxalate decarboxylase, is being developed to treat patients with disorders of oxalate metabolism. Allena Pharmaceuticals COO Louis Brenner said:

Under the terms of the partnership, BIND will use Nanofitins as targeting ligand components for Accurins in immuno-oncology. After the proof-of-concept stage, BIND expects to expand the partnership